Heat Biologics (HTBX) Earning Somewhat Favorable News Coverage, Report Finds
News stories about Heat Biologics (NASDAQ:HTBX) have trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Heat Biologics earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 47.2517803887605 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Griffin Securities Initiates Coverage on Heat Biologics, Inc. (HTBX) (americanbankingnews.com)
- Heat Biologics (HTBX) Plans Common Stock Rights Offering – StreetInsider.com (streetinsider.com)
- Heat Biologics Inc : Heat Biologics Announces Common Stock Rights Offering in Form S-1 Filing (4-traders.com)
- Heat Biologics, Inc. (HTBX) Forecasted to Earn Q3 2017 Earnings of ($0.09) Per Share (americanbankingnews.com)
Heat Biologics (HTBX) opened at 0.6041 on Wednesday. The company’s 50-day moving average is $0.53 and its 200-day moving average is $0.67. Heat Biologics has a 52-week low of $0.46 and a 52-week high of $3.35. The company’s market capitalization is $21.62 million.
Several equities analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Heat Biologics from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a research report on Thursday, May 25th. Noble Financial reissued a “buy” rating on shares of Heat Biologics in a research report on Tuesday, July 4th. ValuEngine lowered shares of Heat Biologics from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 13th. Finally, Griffin Securities assumed coverage on shares of Heat Biologics in a research report on Tuesday, September 12th. They issued a “buy” rating and a $2.25 price objective on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $1.67.
TRADEMARK VIOLATION NOTICE: This report was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://theolympiareport.com/2017/09/20/heat-biologics-htbx-earning-somewhat-favorable-news-coverage-report-finds.html.
About Heat Biologics
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.